Add like
Add dislike
Add to saved papers

Burden of knee osteoarthritis in 204 countries and territories, 1990-2019: Results from the Global Burden of Disease Study 2019.

OBJECTIVE: To report the global, regional, and national estimates of knee osteoarthritis (KOA) burden and associated risk factors (high body mass index (BMI)) by age, sex, and sociodemographic index (SDI) for 204 countries from 1990 to 2019.

METHODS: We analyzed the prevalence, incidence, years lived with disability (YLDs), and age-standardized rates of KOA using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019. Estimates of the KOA burden were derived from data modeled using a Bayesian meta-regression analytical tool (DisMod-MR 2.1).

RESULTS: The global prevalence of KOA in 2019 was approximately 364.6 million (95% UI 315.3-417.4). The age-standardized prevalence in 2019 was 4376.0 per 100,000 (95% UI 3793.0-5004.9), an increase of 7.5% between 1990 and 2019. There were approximately 29.5 million incident cases of KOA in 2019 (95% UI 25.6-33.7), with an age-standardized incidence of 350.3 per 100,000 (95% UI 303.4-398.9). The global age-standardized YLD resulting from KOA was 138.2 (95% UI 68.5-281.3) per 100,000 population in 2019, an increase of 7.8% (95% UI 7.1-8.4) from 1990. Globally in 2019, 22.4% (95% UI 12.1-34.2) of YLD resulting from KOA was attributable to high BMI, an increase of 40.5% since 1990.

CONCLUSION: The prevalence, incidence, YLDs, and age-standardized rates of KOA increased substantially in most countries and regions from 1990 to 2019. Continuous monitoring of this burden is important for establishing appropriate public prevention policies and raising public awareness, especially in high- and high-middle SDI regions. This article is protected by copyright. All rights reserved.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app